Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock

Key Takeaways Boston Scientific is gaining from rapid growth in cardiovascular devices, led by EP and heart products. BSX sees strong global traction for FARAPULSE and 24% WATCHMAN sales growth in Q1 2025. The Zacks Consensus Estimate for BSX's 2025 sales and EPS is rising on strong demand and operating resilience.Boston Scientific (BSX) , a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a Ma ...